Viriom Inc

Viriom Inc. is a commercial and late development stage biotech company developing novel therapies and prevention treatments against HIV and hepatitis B virus (HBV). Viriom's pipeline includes: Elpida® (elsulfavirine), the best-in-class NNRTI that received its first market authorization in 2017; fixed doze combinations with nucleoside reverse transcriptase inhibitors; an innovative extended release weekly oral formulation; and VM1500A - a long acting injectable therapy and pre-exposure prophylaxis. Viriom is also developing a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®) to treat HIV and hepatitis B patients. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries.